Drug Development

Articles

HHS announces $354 million in funding for private industry to manufacture generic drugs in the US from raw materials to finished product.

BARDA Funds US-based Drug Manufacturing Initiative

Participants in two dosing cohorts in Moderna’s mRNA-1273 study reached or exceeded neutralizing antibody titers generally seen in convalescent sera.

mRNA Vaccine Shows Positive Interim Phase I Results

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

As a result of the rising use and development of biological drugs, the biopharma industry is witnessing an increase in the adoption of prefilled syringes.


On Point: Biologics Drive Growth in Pre-Filled Syringes

Brandon Haschke is a product manager for Emerson's Rosemount instrumentation business. 

Single-use processing requires instruments providing the accuracy of traditional technologies but configured in form factors designed specifically for this service

Instrumenting Single-Use Processes

A variety of assays should be used to detect bacterial, fungal, and viral contaminants in the human source cells used for cell therapies.

Detecting Contamination in Cell Therapies

Santen Pharmaceutical has concluded a licensing agreement with jCyte for the development, registration, and commercialization rights to jCell, an investigational retinitis pigmentosa therapy, in Japan, Asia, and Europe.


Santen, jCyte Sign Licensing Contract for Investigational Retinitis Pigmentosa Therapy

The Coalition for Epidemic Preparedness Innovations will invest up to $384 million of additional funding, in addition to the $4 million it invested in March, to advance the clinical development of NVX-CoV2373, Novavax’s COVID-19 vaccine candidate.

Novavax to Receive up to $384 Million in Funding from CEPI for COVID-19 Vaccine Candidate

Catalent will manufacture a mRNA-based COVID-19 vaccine for clinical trials and potential commercialization.

Catalent, Arcturus Therapeutics Sign Vaccine Deal

Trial begins in the US for the Pfizer-BioNTech mRNA COVID-19 vaccine; manufacturing plans announced.

Initial US Patients Dosed in mRNA Vaccine Trial

The extension of the company’s product offerings to include the anti-certolizumab pegol antibodies offers critical reagents for the development of assays for TNF alpha inhibitor biologics and their biosimilars.

Formulation and Drug Delivery